Lyka Labs Limited

Net profit swung from ₹–29.77 Cr loss (Mar 2026) to ₹2.1 Cr profit (Jun 2026) in consecutive quarters; verify whether recent profit reflects operational improvement or one-time gains.

Operating margins fell to –16.02% (Mar 2026), with overall OPM at –2.72%—indicates severe cost-control issues or recurring one-time charges.

Stock declined 34.94% over one year amid persistent losses; PE n/a signals sustained market skepticism about earnings sustainability.

Very low institutional ownership (FII 0.17%, DII 0.66%) despite ₹242.87 Cr market cap—verify whether this reflects company size, governance concerns, execution issues, or sector risks.

Latest quarter (Jun 2026) returned ₹2.1 Cr net profit and 10.87% OPM—if sustained, this marks structural recovery; verify via forward guidance and production capacity.

Stable quarterly revenue of ₹28–₹42 Cr provides operational base; closing the gap between overall –2.72% OPM and Jun 2026's 10.87% would unlock significant bottom-line upside.

ROE at –10.24% and overall OPM at –2.72% well below Jun 2026 operating margin—margin expansion through cost control or product mix could drive profitability without revenue growth.

Verify company's product pipeline, recent regulatory approvals, R&D spend, and therapeutic focus to assess organic growth potential beyond current revenue base.